biosimilars

This squabble between two big drugmakers could have major implications for the U.S. health care system
This squabble between two big drugmakers could have major implications for the U.S. health care system
Marketwatch
JNJ
Pfizer
antitrust
biosimilars
Remicade
Inflectra
Flag link:
Pfizer files US lawsuit against Johnson & Johnson over "anticompetitive" practices related to Remicade biosimilar
Pfizer files US lawsuit against Johnson & Johnson over "anticompetitive" practices related to Remicade biosimilar
First Word Pharma
Pfizer
JNJ
Janssen
Remicade
biosimilars
Inflectra
Flag link:
Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars
Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars
Drug Channels
drug pricing
reimbursement
Remicade
biosimilars
Janssen
Inflectra
Pfizer
Renflexis
Merck
Flag link:
FDA Clears Biotech Drug Copycats, But Buying Them Isn’t So Easy
FDA Clears Biotech Drug Copycats, But Buying Them Isn’t So Easy
Bloomberg
FDA
Avastin
biosimilars
Roche
Flag link:
Samsung Bioepis first to secure EMA backing for Herceptin biosimilar
Samsung Bioepis first to secure EMA backing for Herceptin biosimilar
BioPharma Dive
Samsung Bioepis
EMA
Europe
biosimilars
Herceptin
Roche
breast cancer
Flag link:
Industry Pulse: 10 charts on M&A, I/O and biosimilar threats
Industry Pulse: 10 charts on M&A, I/O and biosimilar threats
BioPharma Dive
M&A
immuno-oncology
biosimilars
Flag link:
FDA commish cheers on biosimilars as Amgen, Allergan score OK for knockoff of Roche’s Avastin
FDA commish cheers on biosimilars as Amgen, Allergan score OK for knockoff of Roche’s Avastin
Endpoints
FDA
Scott Gottlieb
Amgen
Allergan
biosimilars
Mvasi
Roche
Avastin
Flag link:
Interchangeable Biosimilars vs. Biosimilars: Experts Explain Guidance, Discuss Development and Uptake
Interchangeable Biosimilars vs. Biosimilars: Experts Explain Guidance, Discuss Development and Uptake
RAPS.org
FDA
biosimilars
Flag link:
FDA Form 483 for Celltrion May Offer a Glimpse Into Limited Uptake for Remicade Biosimilar
FDA Form 483 for Celltrion May Offer a Glimpse Into Limited Uptake for Remicade Biosimilar
RAPS.org
FDA
Celltrion
biosimilars
Pfizer
Inflectra
Remicade
Flag link:
WHO to Launch Pilot to Prequalify Biosimilars
WHO to Launch Pilot to Prequalify Biosimilars
RAPS.org
WHO
biosimilars
cancer
Flag link:
Key FDA Regulatory Events to Watch Out for in Sep 2017
Key FDA Regulatory Events to Watch Out for in Sep 2017
Yahoo/Zacks.com
FDA
Mylan Labs
Herceptin
biosimilars
trastuzumab
Shingrix
GSK
Pfizer
Sutent
PTC Therapeutics
Translarna
Amgen
Allergan
Avastin
Flag link:
Fresenius closes Merck biosimilar biz purchase
Fresenius closes Merck biosimilar biz purchase
Drug Delivery Business News
Fresenius
Merck KGaA
biosimilars
M&A
Flag link:
Is the System Rigged Against Biosimilars?
Is the System Rigged Against Biosimilars?
Motley Fool
biosimilars
Amgen
Amjevita
Flag link:
Biogen, Samsung Humira copy wins EU approval
Biogen, Samsung Humira copy wins EU approval
Fierce Pharma
Biogen
Samsung Bioepis
Europe
Humira
AbbVie
Imraldi
biosimilars
Flag link:
Remicade Is a Litmus Test for PBMs
Remicade Is a Litmus Test for PBMs
Bloomberg
Remicade
PBMs
biosimilars
CVS Health
Express Scripts
Flag link:
Amgen falls short in Epogen patent appeal but Pfizer stumble delays competition
Amgen falls short in Epogen patent appeal but Pfizer stumble delays competition
Fierce Pharma
Amgen
Epogen
patents
Pfizer
anemia
biosimilars
Flag link:
As Roche wades biosimilar waters, more competitors circle Herceptin
As Roche wades biosimilar waters, more competitors circle Herceptin
BioPharma Dive
Roche
Herceptin
biosimilars
Amgen
Allergan
ABP 980
Celltrion
CT-P6
Flag link:
FDA advances two more Herceptin biosims—this time from Amgen and Teva—as Roche braces for impact
FDA advances two more Herceptin biosims—this time from Amgen and Teva—as Roche braces for impact
Fierce Pharma
FDA
Herceptin
biosimilars
Roche
Amgen
Teva Pharmaceutical
Allergan
Celltrion
Flag link:
Court Ruling on 'Biosimilars' Sets Stage for More Drug Acquisitions
Court Ruling on 'Biosimilars' Sets Stage for More Drug Acquisitions
TheStreet.com
biosimilars
M&A
R&D
Supreme Court
Flag link:
With $39B in cash and biosim threats looming, could Amgen use a deal? Executives say not yet
With $39B in cash and biosim threats looming, could Amgen use a deal? Executives say not yet
Fierce Pharma
Amgen
biosimilars
M&A
Flag link: